[SCHEDULE 13G/A] Rocket Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Rocket Pharmaceuticals disclosure shows that Maverick-affiliated entities and Lee S. Ainslie beneficially hold 8,363,813 shares of common stock, equal to 7.8% of the company based on 107,737,919 shares outstanding. The reported holdings arise from multiple funds and accounts: Maverick Fund USA, Ltd. (1,686,548 shares); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); and separately managed accounts (334,011).

Maverick is identified as the investment adviser with investment discretion over these client accounts, Maverick Capital Management is the general partner, and Lee S. Ainslie III is the manager. The filing reports no sole voting or dispositive power and shared voting and dispositive power over all 8,363,813 shares, indicating a significant institutional stake without unilateral control.

Insights

Securities Analyst

TL;DR Maverick and affiliates hold a material 7.8% stake (8.36M shares), a notable institutional position but not controlling.

The filing documents a substantial passive institutional stake across multiple Maverick funds and managed accounts totaling 8,363,813 shares, representing 7.8% of the outstanding common stock (107,737,919 shares). All power is reported as shared rather than sole, so while this is large enough to warrant attention from investors and the company, it does not convey unilateral voting or disposition control. The structure—advisory relationships and general partner/manager roles—clarifies why beneficial ownership is attributed to both the firm and Mr. Ainslie.

Corporate Governance Expert

TL;DR A meaningful institutional stake is disclosed, but lack of sole voting power limits immediate governance control.

The Schedule 13G shows coordinated beneficial ownership by Maverick entities and Lee S. Ainslie totaling 8,363,813 shares (7.8%). The report specifies shared voting and dispositive power with no sole authority, implying influence potential via engagement or coalition-building rather than direct control. For governance impact, this position is material enough to matter in activist or engagement scenarios, but the filing does not indicate any group formation, solicitation, or intent to influence control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Rocket Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

77313F106

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 77313F106

1

Names of Reporting Persons

Maverick Capital, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,363,813.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,363,813.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,363,813.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 77313F106

1

Names of Reporting Persons

Maverick Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,363,813.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,363,813.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,363,813.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.8 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 77313F106

1

Names of Reporting Persons

Lee S. Ainslie III

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,363,813.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,363,813.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,363,813.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Rocket Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 9 Cedarbrook Drive, Cranbury, NJ, 08512
Item 2.
(a)	Name of person filing: This Schedule 13G (the "Schedule 13G") is being filed on behalf of each of the following persons (each, a "Reporting Person"): (i) Maverick Capital, Ltd. ("Maverick"); (ii) Maverick Capital Management, LLC ("Maverick Capital Management"); and (iii) Lee S. Ainslie III ("Mr. Ainslie"). This Schedule 13G relates to Shares (as defined herein) held for the accounts of Maverick's clients.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of (i) Maverick and Maverick Capital Management is 1900 N. Pearl Street, 20th Floor, Dallas, Texas 75201, and (ii) Mr. Ainslie is 360 South Rosemary Ave., Suite 1440, West Palm Beach, Florida 33401.
(c)	Citizenship: (i) Maverick is a Texas limited partnership; (ii) Maverick Capital Management is a Texas limited liability company; and (iii) Mr. Ainslie is a United States citizen.
(d)	Title of class of securities: Common Stock, $0.01 par value per share
(e)	CUSIP No.: 77313F106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Ownership as of June 30, 2025 is incorporated by reference to items (5) - (9) and (11) of the cover page of each of the Reporting Persons. The ownership percentages are based on 107,737,919 outstanding shares of Common Stock, par value $0.01 per share (the "Shares") of Rocket Pharmaceuticals, Inc. (the "Issuer") as of May 2, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025. Maverick is the investment advisor of (i) Maverick Fund USA, Ltd, a Texas limited partnership, which holds 1,686,548 Shares, (ii) Maverick Fund II, Ltd., a Cayman exempt corporation, which holds 1,727,675 Shares, (iii) Maverick Long Enhanced Fund, Ltd, a Cayman exempt corporation, which holds 1,930,078 Shares, (iv) Maverick HP, L.P., a Delaware limited partnership, which holds 1,726,954 Shares, (v) Maverick Long Fund, Ltd., a Cayman exempt corporation, which holds 958,547 Shares, and (vi) certain separately managed accounts which collectively hold 334,011 Shares. Maverick is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 and, as such, may be deemed to have beneficial ownership of the Shares which are the subject of this filing through the investment discretion it exercises over its clients' accounts. Maverick Capital Management is the General Partner of Maverick. Mr. Ainslie is the manager of Maverick Capital Management.
(b)	Percent of class: (i) Maverick: 7.8% (ii) Maverick Capital Management: 7.8% (iii) Mr. Ainslie: 7.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (i) Maverick: 0 (ii) Maverick Capital Management: 0 (iii) Mr. Ainslie: 0
	(ii) Shared power to vote or to direct the vote: (i) Maverick: 8,363,813 (ii) Maverick Capital Management: 8,363,813 (iii) Mr. Ainslie: 8,363,813
	(iii) Sole power to dispose or to direct the disposition of: (i) Maverick: 0 (ii) Maverick Capital Management: 0 (iii) Mr. Ainslie: 0
	(iv) Shared power to dispose or to direct the disposition of: (i) Maverick: 8,363,813 (ii) Maverick Capital Management: 8,363,813 (iii) Mr. Ainslie: 8,363,813
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Maverick Capital, Ltd.

Signature:	/s/ Trevor Wiessmann*
Name/Title:	By: Maverick Capital Management, LLC, its General Partner By: Lee S. Ainslie III, Manager
Date:	08/14/2025

Maverick Capital Management, LLC

Signature:	/s/ Trevor Wiessmann*
Name/Title:	Lee S. Ainslie III, Manager
Date:	08/14/2025

Lee S. Ainslie III

Signature:	/s/ Trevor Wiessmann*
Name/Title:	Lee S. Ainslie III, Manager
Date:	08/14/2025

Comments accompanying signature: *Under Power of Attorney, dated March 15, 2018

FAQ

How many Rocket Pharmaceuticals (RCKT) shares do Maverick and affiliates own?

They beneficially own 8,363,813 shares of RCKT, as reported in the Schedule 13G/A.

What percentage of RCKT does Maverick's position represent?

The reported stake represents 7.8% of the company's common stock based on 107,737,919 outstanding shares.

Do Maverick or Lee S. Ainslie have sole voting control over these shares?

No. The filing reports 0 shares of sole voting power and indicates shared voting and dispositive power over all reported shares.

Which Maverick funds hold the reported shares?

Holdings are allocated across named accounts including Maverick Fund USA, Ltd. (1,686,548), Maverick Fund II, Ltd. (1,727,675), Maverick Long Enhanced Fund, Ltd. (1,930,078), Maverick HP, L.P. (1,726,954), Maverick Long Fund, Ltd. (958,547), and separately managed accounts (334,011).

Does this filing indicate an intent to influence control of Rocket Pharmaceuticals?

No. The filing includes a certification stating the securities were not acquired for the purpose of changing or influencing control and no group formation is reported.